Kallikrein 13 anticorps (AA 262-277)
Aperçu rapide pour Kallikrein 13 anticorps (AA 262-277) (ABIN289487)
Antigène
Voir toutes Kallikrein 13 (KLK13) AnticorpsReactivité
Hôte
Clonalité
Conjugué
Application
-
-
Épitope
- AA 262-277
-
Purification
- Affinity chromatography purified
-
Immunogène
- KLK-L4 antibody was raised in rabbit using AA 262-277 [IRKYETQQQKWLKGPQ] of the human KLK-L4 protein as the immunogen.
-
Isotype
- IgG
-
-
-
-
Indications d'application
-
WB: 1:500-1:1,000
Optimal conditions should be determined by the investigator. -
Restrictions
- For Research Use only
-
-
-
Concentration
- Lot specific
-
Buffer
- Affinity purified IgG supplied in PBS with 0.02 % NaN3.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium Azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
-
Conseil sur la manipulation
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. -
Stock
- 4 °C/-20 °C
-
Stockage commentaire
- Store at 4 °C for short term storage. Aliquot and store at -20 °C for long term storage.
-
-
- Kallikrein 13 (KLK13) (Kallikrein-Related Peptidase 13 (KLK13))
-
Autre désignation
- KLK-L4
-
Sujet
- Kallikreins are a subgroup of serine proteases and are implicated in carcinogenesis. The novel KLK gene, KLK-L4, is expressed in a variety of tissues including prostate, salivary gland, breast, and testis. Its expression is regulated by steroid hormones in breast cancer cell lines may be involved in the pathogenesis and/or progression of breast cancer.
-
Pathways
- Système du Complément
Antigène
-